{"filing":{"accession_number":"0001104659-26-073015","cik":"0001372299","ticker":"OCGN","company_name":"Ocugen, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"tm2617722d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926073015/tm2617722d1_8k.htm"},"events":[{"id":5307,"run_id":4651,"accession_number":"0001104659-26-073015","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Ocugen held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on four proposals: election of two Class III directors (Kirsten Castillo and Satish Chandran), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on the frequency of future compensation votes. Final vote tallies including For, Against, Abstentions, and Broker Non-Votes were disclosed for each proposal.","company_name":"Ocugen, Inc.","ticker":"OCGN","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6439,"accession_number":"0001104659-26-073015","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder voting results from Ocugen's June 11, 2026 Annual Meeting of Stockholders. The filing reports final vote tallies for four proposals: election of two Class III directors (Kirsten Castillo and Satish Chandran), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on the frequency of future compensation votes. The disclosure includes vote counts (For, Against, Abstentions, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T21:20:07.751414+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5308,"run_id":4651,"accession_number":"0001104659-26-073015","anchor_item_number":"8.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Mohamed Genead, M.D., M.Sc., was appointed as Chief Medical Officer of Ocugen effective June 11, 2026, following his service as Acting/Interim Chief Medical Officer since May 8, 2026.","company_name":"Ocugen, Inc.","ticker":"OCGN","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6440,"accession_number":"0001104659-26-073015","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Mohamed Genead, M.D., M.Sc., as Chief Medical Officer effective June 11, 2026, following his prior service as Acting/Interim Chief Medical Officer since May 8, 2026. This is a material executive appointment to a named officer role at the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T21:20:07.751414+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6439,"accession_number":"0001104659-26-073015","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder voting results from Ocugen's June 11, 2026 Annual Meeting of Stockholders. The filing reports final vote tallies for four proposals: election of two Class III directors (Kirsten Castillo and Satish Chandran), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on the frequency of future compensation votes. The disclosure includes vote counts (For, Against, Abstentions, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T21:20:07.751414+00:00","company_name":"Ocugen, Inc.","ticker":"OCGN","filing_date":"2026-06-11"},{"id":6440,"accession_number":"0001104659-26-073015","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Mohamed Genead, M.D., M.Sc., as Chief Medical Officer effective June 11, 2026, following his prior service as Acting/Interim Chief Medical Officer since May 8, 2026. This is a material executive appointment to a named officer role at the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T21:20:07.751414+00:00","company_name":"Ocugen, Inc.","ticker":"OCGN","filing_date":"2026-06-11"}]}